Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Roger Stupp MD
Roger Stupp MD Advisory Board
Lee Schwartzberg MD, FACP
Lee S. Schwartzberg MD, FACP Advisory Board
Jean-Yves Douillard MD, PhD
Jean-Yves Douillard MD, PhD Advisory Board
See All Experts
featured
Published in Oncology

Expert Opinion / Conference Coverage · June 16, 2015

ASCO 2015 Recap: Breast Cancer, Metastasis, and Prophylactic Mastectomy—Part 2

Jarushka Naidoo MD
Lee Schwartzberg MD, FACP

 

 Save  Recommend
 Share

Additional Info

  1. Traina TA, Miller K, Yardley DA, et al. Results from a phase 2 study of enzalutamide, an androgen receptor inhibitor, in advanced AR+ triple-negative breast cancer. Paper presented at: American Society of Clinical Oncology (ASCO) Annual Meeting; May 29-June 2, 2015; Chicago, IL. Abstract 1003.

Disclosure statements are available on the authors' profiles:

Lee Schwartzberg MD, FACP

Further Reading

Most Read This Week

Recently Updated